Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 15;36(7):360-362.
doi: 10.1093/ajh/hpad031.

Renin-Angiotensin System Inhibitors and the COVID-19 Pandemic

Lweendo Muchaili  1 , Bislom C Mweene  1 , Sepiso K Masenga  1   2   3
Affiliations
Editorial

Renin-Angiotensin System Inhibitors and the COVID-19 Pandemic

Lweendo Muchaili et al. Am J Hypertens. .
No abstract available

Keywords: 2; ACE2; COVID-19 pandemic; SARS-COV; blood pressure; cardiovascular disease; hypertension; renin-angiotensin system inhibitors.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
Figure 1
Figure 1
| Proposed theory of renin-angiotensin system inhibitor mechanism of action to upregulate ACE2 receptors. (A) Angiotensin-converting enzyme inhibitors (ACEI) and (B) angiotensin receptor blockers (ARBs) are two types of medications used to treat high blood pressure and heart failure. ACE inhibitors block the action of ACE that narrows blood vessels and increases blood pressure. ARBs block the action of angiotensin II which narrows blood vessels and increases blood pressure. (C) ACEI and ARBs contribute to upregulate the expression of ACE2 on target cells which SARS-CoV-2 uses as receptors to gain entry into host cells subsequently causing Covid-19. AT, Angiotensin; MAS, Marker Assisted Selected.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

References

    1. Ruilope LM, Tamargo J, Ruiz-Hurtado G.. Renin–angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs. Eur Heart J 2020; 41:2067–2069. doi:10.1093/eurheartj/ehaa487 - DOI - PMC - PubMed
    1. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF.. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol 2018; 71:1474–1482. doi:10.1016/j.jacc.2018.01.058 - DOI - PubMed
    1. Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q, Xue H, Wright JM.. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 2018; 11:CD008170. doi:10.1002/14651858.CD008170.pub3 - DOI - PMC - PubMed
    1. Luca MRD, Sorriento D, Massa D, Valente V, Luise FD, Barbato E, Morisco C.. Effects of inhibition of the renin-angiotensin system on hypertension-induced target organ damage: clinical and experimental evidence. Monaldi Arch Chest Dis 2021;91(1). doi:10.4081/monaldi.2021.1570 - DOI - PubMed
    1. Düsing R. Pharmacological interventions into the renin-angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering. Ther Adv Cardiovasc Dis 2016; 10:151–161. doi:10.1177/1753944716644130 - DOI - PMC - PubMed

Substances